KLK3 and prostate carcinoma: For example, the sensitivity of the prostate-specific antigen (PSA), a serum biomarker for prostate cancer, is greater than 90%, but it has a specificity of only around 25%, resulting in patients needing to undergo a biopsy for the final confirmation of disease [33].